296 related articles for article (PubMed ID: 17560336)
1. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
Vivanco I; Palaskas N; Tran C; Finn SP; Getz G; Kennedy NJ; Jiao J; Rose J; Xie W; Loda M; Golub T; Mellinghoff IK; Davis RJ; Wu H; Sawyers CL
Cancer Cell; 2007 Jun; 11(6):555-69. PubMed ID: 17560336
[TBL] [Abstract][Full Text] [Related]
2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
3. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
4. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
[TBL] [Abstract][Full Text] [Related]
5. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
6. Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury.
Zhang QG; Wu DN; Han D; Zhang GY
FEBS Lett; 2007 Feb; 581(3):495-505. PubMed ID: 17239858
[TBL] [Abstract][Full Text] [Related]
7. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
8. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Lee HY; Srinivas H; Xia D; Lu Y; Superty R; LaPushin R; Gomez-Manzano C; Gal AM; Walsh GL; Force T; Ueki K; Mills GB; Kurie JM
J Biol Chem; 2003 Jun; 278(26):23630-8. PubMed ID: 12714585
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review).
Zhao HF; Wang J; Tony To SS
Int J Oncol; 2015 Aug; 47(2):429-36. PubMed ID: 26082006
[TBL] [Abstract][Full Text] [Related]
10. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
RodrÃguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?
Colakoglu T; Yildirim S; Kayaselcuk F; Nursal TZ; Ezer A; Noyan T; Karakayali H; Haberal M
Am J Surg; 2008 Jun; 195(6):719-25. PubMed ID: 18440486
[TBL] [Abstract][Full Text] [Related]
13. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between PTEN expression and PI3K/AKT signal pathway in colon carcinoma].
Qi JK; Huang XL; Meng ZM; Gan HT; Fu DG
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):644-6, 654. PubMed ID: 19764563
[TBL] [Abstract][Full Text] [Related]
15. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
16. Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway.
Kim JH; Lee G; Cho YL; Kim CK; Han S; Lee H; Choi JS; Choe J; Won MH; Kwon YG; Ha KS; Kim YM
Eur J Pharmacol; 2009 Jan; 602(2-3):422-31. PubMed ID: 19027002
[TBL] [Abstract][Full Text] [Related]
17. [Impact of PTEN gene knockout in human breast carcinoma MCF-7 cells on activity of JNK pathway].
Jin Y; Hu JL; Xiao L; Cui W
Ai Zheng; 2008 Dec; 27(12):1239-43. PubMed ID: 19079986
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
Xi Y; Chen Y
J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
[TBL] [Abstract][Full Text] [Related]
19. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
20. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.
You D; Xin J; Volk A; Wei W; Schmidt R; Scurti G; Nand S; Breuer EK; Kuo PC; Breslin P; Kini AR; Nishimura MI; Zeleznik-Le NJ; Zhang J
Cell Rep; 2015 Mar; 10(12):2055-68. PubMed ID: 25801032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
